Core Viewpoint - Scienture Holdings, Inc. has announced the shipment of launch quantities of Arbli (losartan potassium) Oral Suspension, marking a significant milestone for the company as it prepares for the commercial launch of this novel product aimed at treating hypertension and related conditions [1][5]. Product Overview - Arbli is the first and only FDA-approved ready-to-use oral liquid formulation of losartan in the U.S. market, designed for patients over 6 years old [2][6]. - The product is indicated for the treatment of hypertension, reduction of stroke risk in patients with hypertension and left ventricular hypertrophy, and treatment of diabetic nephropathy in certain type 2 diabetes patients [8][10]. - Arbli offers a tailored approach for patients who require or prefer a liquid option, ensuring easier and safer dosing without the need for compounding [3][4]. Market Context - Losartan is classified as an angiotensin receptor blocker (ARB) and is one of the most prescribed medications for hypertension, with total annual sales of approximately $276 million and a prescription volume of 69 million in the U.S. as of March 2025 [4]. - The global market for losartan potassium was valued at approximately $1.5 billion in sales in 2024 [4]. Company Strategy - The shipment of Arbli to the distribution center and the receipt of the first order are seen as critical milestones in Scienture's efforts to deliver the product to healthcare providers [5]. - The company emphasizes its commitment to quality by ensuring compliance with Good Manufacturing Practices (GMP) and Good Distribution Practices (GDP) standards [5]. Product Specifications - Arbli is available in a 165 mL bottle as a peppermint-flavored suspension that does not require refrigeration and has a shelf life of 24 months when stored at room temperature [6].
SCIENTURE announces the shipment of launch quantities of Arbli™ (losartan potassium Oral Suspension) to its 3PL/Distribution Center and receipt of first wholesaler order, marking major commercialization milestones.